Nefopam (hydrochloride)

Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2].

Product Specifications

CAS Number

[23327-57-3]

Product Name Alternative

Fenazoxine (hydrochloride)

UNSPSC

12352005

Hazard Statement

H301+H311+H331

Target

β-catenin

Type

Reference compound

Related Pathways

Stem Cell/Wnt

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Nefopam-hydrochloride.html

Purity

99.92

Solubility

DMSO : 12.5 mg/mL (ultrasonic) |H2O : 12.5 mg/mL (ultrasonic)

Smiles

CN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3C1.[H]Cl

Molecular Formula

C17H20ClNO

Molecular Weight

289.80

Precautions

H301+H311+H331

References & Citations

[1]Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27 (2) :103-11.|[2]Poon R, et al. A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders. PLoS One. 2012;7 (5) :e37940.|[3]Baht GS, et al. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair. Bone. 2017 May;98:31-36.